Migraine CGRP monoclonal antibody observational study
Summary
CGRP monoclonal antibodies (mAbs) have been effective for many migraine patients who previously failed the standard treatments. The purpose of this research study is to assess early results of all four currently available CGRP mAbs (fremanezumab, galcanezumab, erenumab and eptinezumab), with the focus on their tolerability and safety. Also, this study will try to answer the important question of whether non-responders to treatment with one of the CGRP mAbs benefit from switch to another other Ab or not.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 90
Inclusion criteria:
1. 18 years of age or older.
2. Have a diagnosis of migraines, with four or more migraine days per month.
3. Have received one of the following mentioned treatments for at least one month: galcanezumab 240 mg, galcanezumab 120 mg, erenumab 140 mg, erenumab 70 mg, fremanezumab 675 mg, fremanezumab 225 mg, eptinezumab 100 mg IV or eptinezumab 300 mg IV.
Participate
Additional information
Contact information
Research Coordinator CHAMP Office: 403-956-3441 mary.chou@ucalgary.ca
Principal investigator:
Farnaz Amoozegar
Clinical trial:
No
REB-ID:
REB22-1075